## Juan P De Torres

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7770435/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chest <scp>CT</scp> â€assessed comorbidities and allâ€cause mortality risk in <scp>COPD</scp> patients in the <scp>BODE</scp> cohort. Respirology, 2022, 27, 286-293.	2.3	26
2	Severe exacerbations and mortality in <scp>COPD</scp> : Importance of both body and mind. Respirology, 2022, 27, 256-257.	2.3	0
3	Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers. Journal of Clinical Medicine, 2021, 10, 489.	2.4	2
4	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Archivos De Bronconeumologia, 2021, 57, 36-41.	0.8	9
5	Recent Advances in the Physiological Assessment of Dyspneic Patients with Mild COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 374-384.	1.6	4
6	Reduced exercise tolerance in mild chronic obstructive pulmonary disease: The contribution of combined abnormalities of diffusing capacity for carbon monoxide and ventilatory efficiency. Respirology, 2021, 26, 786-795.	2.3	12
7	Lung Cancer Screening in Patients With Chronic Obstructive Pulmonary Disease: Do the Benefits Outweigh the Risks?. Archivos De Bronconeumologia, 2021, 57, 679-680.	0.8	1
8	Endobronchial autologous bone marrow–mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Research, 2021, 7, 00773-2020.	2.6	10
9	Qualitative Components of Dyspnea during Incremental Exercise across the COPD Continuum. Medicine and Science in Sports and Exercise, 2021, 53, 2467-2476.	0.4	13
10	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. Chest, 2021, 160, 481-490.	0.8	16
11	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Archivos De Bronconeumologia, 2021, 57, 533-539.	0.8	6
12	Mechanisms of Exertional Dyspnea in Patients with Mild COPD and a Low Resting DL <sub>CO</sub> . COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 501-510.	1.6	8
13	Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest, 2021, 160, 872-878.	0.8	22
14	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Archivos De Bronconeumologia, 2021, 57, 36-41.	0.8	3
15	Dyspnea in COPD: New Mechanistic Insights and Management Implications. Advances in Therapy, 2020, 37, 41-60.	2.9	105
16	Lung Function Testing in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 347-366.	2.1	10
17	<p>Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD</p> . International Journal of COPD, 2020, Volume 15, 1823-1829.	2.3	5
18	Sex differences between women and men with COPD: A new analysis of the 3CIA study. Respiratory Medicine, 2020, 171, 106105.	2.9	50

#	Article	IF	CITATIONS
19	A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients. International Journal of COPD, 2020, Volume 15, 1801-1811.	2.3	2
20	Lung cancer screening: how do we make it better?. Quantitative Imaging in Medicine and Surgery, 2020, 10, 533-536.	2.0	3
21	Prevalence and burden of bronchiectasis in a lung cancer screening program. PLoS ONE, 2020, 15, e0231204.	2.5	13
22	Resting <i>V</i> ′ <sub>E</sub> / <i>V</i> ′ <sub>CO<sub>2</sub> </sub> adds to inspiratory capacity to predict the burden of exertional dyspnoea in COPD. European Respiratory Journal, 2020, 56, 1902434.	6.7	4
23	Emphysema phenotypes and lung cancer risk. PLoS ONE, 2019, 14, e0219187.	2.5	22
24	B Cell–Adaptive Immune Profile in Emphysema-Predominant Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1434-1439.	5.6	22
25	Plasma metabolomics and clinical predictors of survival differences in COPD patients. Respiratory Research, 2019, 20, 219.	3.6	22
26	Prognostic Validation Using GesEPOC 2017 Severity Criteria. Archivos De Bronconeumologia, 2019, 55, 409-413.	0.8	4
27	Interstitial Lung Abnormalities and LungÂCancer Risk in the National LungÂScreening Trial. Chest, 2019, 156, 1195-1203.	0.8	61
28	The effect of radiographic emphysema in assessing lung cancer risk. Thorax, 2019, 74, 858-864.	5.6	24
29	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	1.6	7
30	Survival with Parenchymal and Pleural Invasion of Non–Small Cell Lung Cancers Less than 30 mm. Journal of Thoracic Oncology, 2019, 14, 890-902.	1.1	25
31	Validación pronóstica según los criterios de la GesEPOC 2017. Archivos De Bronconeumologia, 2019, 55, 409-413.	0.8	18
32	The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial–American College of Radiology Image Network Cohort. Annals of the American Thoracic Society, 2019, 16, 641-644.	3.2	4
33	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax, 2019, 74, 371-379.	5.6	9
34	Trabecular bone score in active or former smokers with and without COPD. PLoS ONE, 2019, 14, e0209777.	2.5	6
35	The Global Burden of Pulmonary Diseases: Most Prevalent Problems and Opportunities for Improvement. Annals of Global Health, 2019, 85, .	2.0	82
36	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	5.5	21

#	Article	IF	CITATIONS
37	Changes and Clinical Consequences of Smoking Cessation in Patients With COPD. Chest, 2018, 154, 274-285.	0.8	6
38	Gas exchange and breathing pattern in women with postmenopausal bone fragility. Respiratory Medicine, 2018, 137, 141-146.	2.9	3
39	The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study. Respirology, 2018, 23, 485-491.	2.3	9
40	Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 463-469.	5.6	63
41	Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer. Cancer Medicine, 2018, 7, 3474-3483.	2.8	11
42	Temporal transitions in COPD severity stages within the GOLD 2017 classification system. Respiratory Medicine, 2018, 142, 81-85.	2.9	12
43	Pulmonary arterial enlargement predicts long-term survival in COPD patients. PLoS ONE, 2018, 13, e0195640.	2.5	13
44	Fully automated bone mineral density assessment from low-dose chest CT. , 2018, , .		2
45	Lung Cancer and Emphysema. Archivos De Bronconeumologia, 2017, 53, 47-48.	0.8	2
46	¿Es realmente la enfermedad pulmonar obstructiva crónica una enfermedad progresiva?. Archivos De Bronconeumologia, 2017, 53, 362-363.	0.8	6
47	Is Chronic Obstructive Pulmonary Disease Really a Progressive Disease?. Archivos De Bronconeumologia, 2017, 53, 362-363.	0.8	2
48	Chronic Obstructive Pulmonary Disease in Women. Is it Different?. Archivos De Bronconeumologia, 2017, 53, 222-227.	0.8	3
49	Enfermedad pulmonar obstructiva crónica en mujeres: ¿somos diferentes?. Archivos De Bronconeumologia, 2017, 53, 222-227.	0.8	10
50	Telomere length, COPD and emphysema as risk factors for lung cancer. European Respiratory Journal, 2017, 49, 1601521.	6.7	19
51	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	6.7	53
52	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2017, 53, 574-582.	0.8	0
53	Diferencias entre GesEPOC y GOLD en el año 2017. Archivos De Bronconeumologia, 2017, 53, 295-296.	0.8	1
54	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162.	6.7	122

#	Article	IF	CITATIONS
55	Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2017, 18, 1097.e11-1097.e24.	2.5	38
56	Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. Respiratory Research, 2017, 18, 59.	3.6	46
57	Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. Chest, 2017, 151, 358-365.	0.8	29
58	Cáncer de pulmón y enfisema. Archivos De Bronconeumologia, 2017, 53, 47-48.	0.8	4
59	Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respiratory Research, 2017, 18, 175.	3.6	11
60	Is COPD a Progressive Disease? A Long Term Bode Cohort Observation. PLoS ONE, 2016, 11, e0151856.	2.5	10
61	Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. Chest, 2016, 149, 936-942.	0.8	55
62	The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. Lung Cancer, 2016, 97, 28-34.	2.0	45
63	Prognostic assessment in COPD without lung function: the B-AE-D indices. European Respiratory Journal, 2016, 47, 1635-1644.	6.7	37
64	Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT. Lung Cancer, 2016, 97, 81-86.	2.0	34
65	Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?. Multidisciplinary Respiratory Medicine, 2016, 11, 17.	1.5	10
66	Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest, 2016, 149, 45-52.	0.8	227
67	Simplifying the Guidelines: The 10 COPD Commandments. Archivos De Bronconeumologia, 2016, 52, 179-180.	0.8	7
68	Simplificando las guÃas: los 10 mandamientos de la EPOC. Archivos De Bronconeumologia, 2016, 52, 179-180.	0.8	11
69	BODE Index: A Good Quality of Life Marker in Chronic Obstructive Pulmonary Disease Patients. Archivos De Bronconeumologia, 2015, 51, 311-312.	0.8	2
70	What pulmonologists think about the asthma–COPD overlap syndrome. International Journal of COPD, 2015, 10, 1321.	2.3	35
71	IL-8Gene Variants are Associated with Lung Function Decline and Multidimensional BODE Index in COPD Patients But Not with Disease Susceptibility: A Validation Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2015, 12, 55-61.	1.6	13
72	Lung Cancer Screening: The Balance between Harm and Benefit. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1209-1209.	5.6	1

#	Article	IF	CITATIONS
73	Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD. Chest, 2015, 148, 159-168.	0.8	96
74	Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. Development and Validation of the COPD Lung Cancer Screening Score. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 285-291.	5.6	138
75	Improving Selection Criteria for Lung Cancer Screening. The Potential Role of Emphysema. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 924-931.	5.6	90
76	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respiratory Medicine,the, 2015, 3, 443-450.	10.7	125
77	COPD comorbidities network. European Respiratory Journal, 2015, 46, 640-650.	6.7	145
78	Cribado de cáncer de pulmón: catorce años de experiencia del Programa Internacional de Detección Precoz de Cáncer de Pulmón con TBDR de Pamplona (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	59
79	Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP). Archivos De Bronconeumologia, 2015, 51, 169-176.	0.8	28
80	Should Age Be Part of Multidimensional Indices of Risk in Chronic Obstructive Pulmonary Disease. Respiration, 2015, 89, 274-275.	2.6	0
81	Efectos inmunomoduladores del glatirÃ;mero acetato y su potencial papel en la reactivación de la tuberculosis pulmonar. Archivos De Bronconeumologia, 2015, 51, 656-657.	0.8	2
82	Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. European Respiratory Journal, 2014, 44, 324-331.	6.7	57
83	Longitudinal assessment in COPD patients: multidimensional variability and outcomes. European Respiratory Journal, 2014, 43, 745-753.	6.7	37
84	New GOLD classification: longitudinal data on group assignment. Respiratory Research, 2014, 15, 3.	3.6	42
85	Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax, 2014, 69, 799-804.	5.6	82
86	Response to "Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients― Respiratory Medicine, 2014, 108, 815.	2.9	1
87	Clinical Application of the COPD Assessment Test. Chest, 2014, 146, 111-122.	0.8	20
88	Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study. PLoS ONE, 2014, 9, e89866.	2.5	43
89	Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study. Respiratory Medicine, 2013, 107, 702-707.	2.9	50
90	Distribution and Prognostic Validity of the New Global Initiative for Chronic Obstructive Lung Disease Grading Classification. Chest, 2013, 143, 694-702.	0.8	120

#	Article	IF	CITATIONS
91	Multicomponent indices to predict survival in COPD: the COCOMICS study. European Respiratory Journal, 2013, 42, 323-332.	6.7	93
92	Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer. Journal of the National Cancer Institute, 2013, 105, 1385-1393.	6.3	127
93	Smokers with CT Detected Emphysema and No Airway Obstruction Have Decreased Plasma Levels of EGF, IL-15, IL-8 and IL-1ra. PLoS ONE, 2013, 8, e60260.	2.5	9
94	Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2013, 8, e65593.	2.5	20
95	Lung Cancer Is More Common in Early GOLD Stages of COPD: Not a Spurious Association: Reply. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1128-1129.	5.6	1
96	Chronic obstructive pulmonary disease History Assessment in Spain: una valoración multidimensional de la enfermedad pulmonar obstructiva crónica. Método y organización del trabajo. Archivos De Bronconeumologia, 2012, 48, 453-459.	0.8	22
97	Inflammatory and repair serum biomarker pattern. Association to clinical outcomes in COPD. Respiratory Research, 2012, 13, 71.	3.6	65
98	Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 155-161.	5.6	946
99	Robust, Standardized Quantification of Pulmonary Emphysema in Low Dose CT Exams. Academic Radiology, 2011, 18, 1382-1390.	2.5	14
100	Six-Minute Walking Distance in Women with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 300-305.	1.6	10
101	Gender Differences in Plasma Biomarker Levels in a Cohort of COPD Patients: A Pilot Study. PLoS ONE, 2011, 6, e16021.	2.5	44
102	Emphysema Presence, Severity, and Distribution Has Little Impact on the Clinical Presentation of a Cohort of Patients With Mild to Moderate COPD. Chest, 2011, 139, 36-42.	0.8	29
103	Evaluation of micro-CT for emphysema assessment in mice: comparison with non-radiological techniques. European Radiology, 2011, 21, 954-962.	4.5	38
104	TNFA-863 polymorphism is associated with a reduced risk of Chronic Obstructive Pulmonary Disease: A replication study. BMC Medical Genetics, 2011, 12, 132.	2.1	13
105	FDG Uptake and the Diagnostic Yield of Transbronchial Needle Aspiration. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 7-14.	1.4	5
106	The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1015-1021.	5.6	197
107	Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 913-919.	5.6	266
108	Diagnostic Yield of Electromagnetic Navigation Bronchoscopy Is Highly Dependent on the Presence of a Bronchus Sign on CT Imaging. Chest, 2010, 138, 1316-1321.	0.8	214

#	Article	IF	CITATIONS
109	Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT. European Radiology, 2010, 20, 2600-2608.	4.5	34
110	Microalbuminuria and Hypoxemia in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1004-1010.	5.6	72
111	Sex differences in mortality in patients with COPD. European Respiratory Journal, 2009, 33, 528-535.	6.7	122
112	Low-dose Volumetric Computed Tomography for Quantification of Emphysema in Asymptomatic Smokers Participating in an Early Lung Cancer Detection Trial. Journal of Thoracic Imaging, 2009, 24, 206-211.	1.5	27
113	Women with chronic obstructive pulmonary disease: an emerging phenotype of the disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 821-830.	0.2	3
114	Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg. Respiratory Medicine, 2008, 102, 1026-1032.	2.9	37
115	Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD. Chest, 2008, 134, 746-752.	0.8	254
116	C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD. Chest, 2008, 133, 1336-1343.	0.8	127
117	Assessing the Relationship Between Lung Cancer Risk and Emphysema Detected on Low-Dose CT of the Chest. Chest, 2007, 132, 1932-1938.	0.8	385
118	Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respiratory Research, 2007, 8, 18.	3.6	61
119	COPD heterogeneity: gender differences in the multidimensional BODE index. International Journal of COPD, 2007, 2, 151-5.	2.3	5
120	Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes, 2006, 4, 72.	2.4	98
121	Gender and COPD in Patients With Chronic Respiratory Insufficiency Requiring Domiciliary Oxygen Therapy. Chest, 2006, 129, 827-828.	0.8	0
122	Riot control agents and their respiratory effects. Respiratory Medicine Extra, 2006, 2, 13-15.	0.1	1
123	Gender and Chronic Obstructive Pulmonary Disease in High-Risk Smokers. Respiration, 2006, 73, 306-310.	2.6	43
124	C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. European Respiratory Journal, 2006, 27, 902-907.	6.7	240
125	Gender and COPD in Patients Attending a Pulmonary Clinic. Chest, 2005, 128, 2012-2016.	0.8	214
126	Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 591-597.	5.6	514

#	Article	IF	CITATIONS
127	Electromyographic validation of the mouth pressure–time index: a noninvasive assessment of inspiratory muscle load. Respiratory Medicine, 2003, 97, 1006-1013.	2.9	7
128	Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest, 2002, 121, 1092-1098.	0.8	214
129	The association with COPD. , 0, , 38-49.		0